PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a healthcare company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, today announced that preliminary results from its U.S. 40-patient feasibility study, in which an enhanced formulation of the company’s Microcyn Technology-based hydrogel was used in the treatment of acne, are highly encouraging and warrant further examination.
